Michelle Papadimitriou joined Certa Therapeutics as a Research and Commercialisation Associate in 2018. She has been Research and Development Director since 2022.
Michelle has more than 5 years of experience in drug development, managing pre-clinical efficacy, safety, and toxicology studies to progress drug candidates to Phase 1 and Phase 2 clinical trials. She also has more than 15 years of experience in biomedical research.
Concurrent to this role, Michelle was Head of Research and Development with OccuRx (2020-2024).
Michelle has a PhD from the University of Melbourne in immunogenetics and has completed a post-doctoral fellowship at the Centre for Regenerative Therapies Dresden (Germany).
